1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Drugs In Development, 2022, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 49, 28, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gallbladder Cancer - Overview
- Gallbladder Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gallbladder Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gallbladder Cancer - Companies Involved in Therapeutics Development
- Gallbladder Cancer - Drug Profiles
- Gallbladder Cancer - Dormant Projects
- Gallbladder Cancer - Discontinued Products
- Gallbladder Cancer - Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2020: Strata Oncology partners with Elevation Oncology to accelerate enrollment of CRESTONE study for patients with rare NRG1 gene fusions
- Jun 04, 2018: Infinity Reports IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study at American Society of Clinical Oncology Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Gallbladder Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gallbladder Cancer - Dormant Projects, 2022
- Gallbladder Cancer - Discontinued Products, 2022
- Number of Products under Development for Gallbladder Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- ABL Bio Inc
- Advenchen Laboratories LLC
- Agastiya Biotech LLC
- Akeso Inc
- Alkermes Plc
- Almac Discovery Ltd
- Alphamab Oncology
- Andes Biotechnologies
- Apexian Pharmaceuticals Inc
- Apollomics Inc
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Bayer AG
- BeiGene Ltd
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- CanBas Co Ltd
- Celltrion Inc
- Cornerstone Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Delta-Fly Pharma Inc
- Diverse Biotech Inc
- Eisai Co Ltd
- Elevation Oncology Inc
- Eli Lilly and Co
- Ennaid Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- GeneQuantum Healthcare Suzhou Co Ltd
- GenFleet Therapeutics (Shanghai) Inc
- Huabo Biopharm (Shanghai) Co Ltd
- Hutchison MediPharma Ltd
- Infinity Pharmaceuticals Inc
- Innopharmax Inc
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Kringle Pharma Inc
- Kyowa Kirin Co Ltd
- Leap Therapeutics Inc
- LipoMedix Pharmaceutical Inc
- MacroGenics Inc
- Medicenna Therapeutics Corp
- Merck & Co Inc
- Merck KGaA
- Mina Therapeutics Ltd
- Mirati Therapeutics Inc
- Molecular Templates Inc
- Noxopharm Ltd
- NuCana Plc
- Ono Pharmaceutical Co Ltd
- Perseus Proteomics Inc
- Pfizer Inc
- Promontory Therapeutics Inc
- Puma Biotechnology Inc
- Recordati SpA
- Redx Pharma Plc
- RemeGen Co Ltd
- Sanofi
- Seagen Inc
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- SMT bio Co Ltd
- Suzhou Hitebio Biotechnology Co Ltd
- Symphogen A/S
- Taiho Oncology Inc
- TOT Biopharm Co Ltd
- Transcenta Holding Ltd
- TransThera Sciences (Nanjing) Inc
- Turning Point Therapeutics Inc
- VasGene Therapeutics Inc
- Xencor Inc
- XuanZhu Biological Technology Co Ltd
- Zymeworks Inc
